Luitpold, the makers of Adequan (polysulfated glycosaminoglycan) announced that veterinarians began receiving shipments of the drug on September 13. However, they said, the drug remains in limited supply, and the initial shipments will not meet current market demand. ?We are working diligently to release additional product to the market and will provide updates as they become available. Quality and integrity remain our highest priorities,? as stated in a 9-16-13 Luitpold press release.
As you may recall, Luitpold has made significant investments in upgrading its manufacturing facilities, per the FDA, earlier this year. ?The time spent making these upgrades impacted our ability to keep up with demand,? said the recent press release.
For more information on Adequan vs. Legend, see September 2011 issue.
